|
|
Post by mnholdem on Feb 17, 2020 19:02:39 GMT -5
Regardless, this poll is scheduled to lock tomorrow at 3pm CST.
|
|
|
|
Post by mnholdem on Feb 17, 2020 15:12:26 GMT -5
There are a number of possibilities regarding candidates inclusion on the company's proxy for annual shareholder voting. The shareholder recommendations for new directors may still be being evaluated by the BoD's Nominating and Governance Committee. As one of those persons who was recommended, I was contacted by MannKind Corporation and was required to complete and submit specific information. I also received the results (by USPS) of the results of company's background check. I have not yet been informed by the company as to whether the Committee has qualified these new shareholder recommendations or whether they have been deemed as nominees for inclusion on the 2020 proxy vote for board directors. A shareholder/group with 3% of outstanding shares can notify the company of their intent to require that MannKind include their nominees on the company's proxy materials per SEC Rule 14a-11. A shareholder, or group like HfM, can also make this request official by filing a Schedule 14N with the SEC, but I have not been informed of any SEC filing to date, so I assume that the corporation is still working with HfM to process the director recommendations. --- Again, I should remind you that I was recommended to the company for a directors position by the activist shareholder group known as HopeForMannKind (HfM) based on recommendations by shareholders, but I am not actively participating with HfM nor am I aware of their current activities. Regardless, Bill has a history of sharing news when it happens, so I assume that there have been no recent developments or communications from MannKind Corporation. Last year, as I recall, the official proxy mailing date was March 28. I don't know when MannKind Corporation will be scheduling its ASM this year, but I suspect that we'll hear something soon regarding the HfM recommendations.  |
|
|
|
Post by mnholdem on Feb 16, 2020 8:58:22 GMT -5
I was wondering if somebody would tell you that the stock market will be closed on Presidents Day.  We have quite the support team here at ProBoards-MNKD.  |
|
|
|
Post by mnholdem on Feb 15, 2020 13:45:29 GMT -5
Retention is a combination of two main factors; quality of experience, insurance coverage. Many posters have implied that Mannkind diabetes educators are incompetent and only the experts at VDEX know the secret sauce required to ensure quality of experience. My sentiment is that is not likely. mnholdem used to track Afrezza tier placement in the insurance formularies and post his findings. I think he gave up doing that a long time ago. My sentiment is the big nut to crack for retention is insurance coverage. I’ve been meaning to explain my discontinued coverage. Some time ago, formularylookup.com started requiring registration. Although it was free, admission is at their discretion. I received the message “you will be contacted” but I never received anything. So I no longer have access to FormularyLookup’s channel coverage for Afrezza. |
|
|
|
Post by mnholdem on Feb 11, 2020 17:26:43 GMT -5
Source: www.globaldata.com/vildagliptins-affordability-will-provide-competitive-advantage-to-eris-and-cipla-in-crowded-indian-diabetes-market-says-globaldata/Feb 11, 2020
Novartis has recently sold its anti-diabetic drug vildagliptin (branded as Zomelis, Vysov and Vysov M) to Ahmedabad-based Eris Lifesciences and Mumbai-based pharmaceutical major Cipla Ltd, in India. The orally active, potent and selective dipeptidyl peptidase -4 (DPP-4) inhibitor’s patent has expired in India leading to increased affordability of vildagliptin. Product acquisition and increased affordability of vildagliptin will provide a competitive advantage to both the companies in a market crowded with several players, says GlobalData, a leading data and analytics company.
...Cipla views diabetes as a main therapeutic area of focus, due to the large market opportunity in India. In the past, the company has collaborated with Eli Lilly to market and distribute Basaglar (insulin glargine), with Janssen to market canagliflozin under brand name Prominad and with Mannkind USA to market inhaled insulin Afrezza, which is in clinical development. Cipla will be responsible to get the regulatory approval for Afrezza in India.
|
|
|
|
Post by mnholdem on Feb 10, 2020 16:43:21 GMT -5
Hey give the guy a break... he’s only humann (LOL).
|
|
|
|
Post by mnholdem on Feb 9, 2020 11:17:50 GMT -5
I’m of the opinion that if there is sabotage that it’s unintentional. In my opinion the business plan created by the current CEO is bad because it appears to follow the Big Pharma SOP for launching new drugs.
In the right hands, Technosphere Insulin has the potential to disrupt the diabetes treatment industry and, as is the case with all disruptive technology, you must either go big or go home.
MC is afraid to go big and, frankly, doesn’t possess the skill set needed for successfully introducing disruptive medical innovations.
This may sound harsh but MannKind’s current CEO is not a leader. He is a follower.
|
|
|
|
Post by mnholdem on Feb 4, 2020 10:43:26 GMT -5
It's true! I had to towel off after trying to make sense of the coronavirus diagram you posted. |
|
|
|
Post by mnholdem on Feb 4, 2020 10:38:02 GMT -5
Mike McHargue spent fifteen years successfully using science-based methodologies to help companies to figure out and understand how their customers think. Mike says that their are two critical mistakes that brands make when talking about their products and services: 1. They fail to focus on the aspects of their offer that will help people to survive and thrive: - If you position your product as anything but an aid in helping people survive, thrive, be accepted, find love, etc., good luck selling anything to anybody. A story about anything else will not work to captivate an audience. Nobody's interested.
2. They cause their customers to burn too many calories in an effort to understand what they offer: - McHargue wrote, " Processing information demands that the brain burn calories." in other words, there's a mechanism within the brain that is designed to "tune out" what is confusing. --- The most powerful tool that MannKind can use to organize information that doctors, patients and payers can understand is story. Story is a sense-making device. It identifies our ambition, defines the challenges that are keeping us from achieving that ambition, and provides a plan to help us conquer those challenges. There are practical steps that MannKind can take to make sure people see us, hear us, and understand exactly why they simply must use our product. I feel better knowing that I am on a weight-loss program sitting here reading PB!  No pain, no gain! We need more informative posts!  |
|
|
|
Post by mnholdem on Feb 4, 2020 10:27:16 GMT -5
Dr. Grunberger noted the lung respiratory volume decline and was quoted, “But once you stop using the drug, FEV1 reverts to normal,” he said. “So, there does not appear to be lasting damage to your lungs and respiratory ability.”
|
|
|
|
Post by mnholdem on Feb 4, 2020 8:43:55 GMT -5
When your label creates a barrier, you work around it. It's like a sign I once had in my office that said, "If things don't go right, then go left". To uvula's point, the website is a place and his question was, essentially, how many people go to the websites of the drugs they take? That's a very good point, IMO.
MannKind must strive to use multiple communication tools to reach people. However, they need to have their message right before launching a campaign to engage the public and win hearts and minds.
|
|
|
|
Post by mnholdem on Feb 4, 2020 8:31:39 GMT -5
Mike McHargue spent fifteen years successfully using science-based methodologies to help companies to figure out and understand how their customers think. Mike says that there are two critical mistakes that brands make when talking about their products and services: 1. They fail to focus on the aspects of their offer that will help people to survive and thrive: - If you position your product as anything but an aid in helping people survive, thrive, be accepted, find love, etc., good luck selling anything to anybody. A story about anything else will not work to captivate an audience. Nobody's interested.
2. They cause their customers to burn too many calories in an effort to understand what they offer: - McHargue wrote, "Processing information demands that the brain burn calories." in other words, there's a mechanism within the brain that is designed to "tune out" what is confusing. --- The most powerful tool that MannKind can use to organize information that doctors, patients and payers can understand is story. Story is a sense-making device. It identifies our ambition, defines the challenges that are keeping us from achieving that ambition, and provides a plan to help us conquer those challenges. There are practical steps that MannKind can take to make sure people see us, hear us, and understand exactly why they simply must use our product. |
|
|
|
Post by mnholdem on Feb 4, 2020 8:00:11 GMT -5
I imagine that you folks get tired of me repeating my thoughts about MannKind needing to improve its image? I hope that the promise given on this new website isn't just another Fad-of-the-Month for management. One book that is given to all management employees for the multiple companies where I work is "BUILDING A STORY BRAND - Clarify Your Message So Customers Will Listen" by New York Times bestselling author Donald Miller. Here are some introductory messages that I think may apply to MannKind Corporation: "Customers don't care about your story; they care about their own. Your customer should be the hero of the story, not your brand. This is the secret every phenomenally successful business understands.""The fact is, pretty websites don't sell things. Words sell things. If we haven't clarified our message, our customers won't listen. If we pay a lot of money to a design agency without first clarifying our message...the only thing a potential customer will hear is noise.""The reality is we aren't just in a race to get our products to market; we're also in a race to communicate why our customers need those products in their lives. Even if we have the best product...we'll lose to an inferior product if our competitor's offer is communicated more clearly."
"How many sales are we missing our on because customers can't figure our what we offer within five seconds of visiting our website?"
---I am cautiously optimistic about the new message about what MannKind offers to patients. "A Life More Humann." |
|
|
|
Post by mnholdem on Feb 2, 2020 8:13:12 GMT -5
Nice work, neil36. |
|
|
|
Post by mnholdem on Feb 1, 2020 9:39:58 GMT -5
The FDA announced years ago that it would begin accepting real-world data in its ongoing evaluations of drugs. Since launch there have been over 118,000 prescriptions written for Afrezza. mnkd.proboards.com/thread/1742/afrezza-script-counts-symphony-dataCoupled with MannKind CMO David Kendall's post-hoc lung safety data study presentation and the FDA, a cause can (and perhaps should) be made that the time has come to determine whether the requisite post market 5-year lung safety study is even necessary. Sufficient data may be available to amend the label or to require a shorter study at this point by accepting real world data, evaluation of total reported lung issues (major adverse event) and post-hoc data. The is an important issue and the removal of the black box warning could be a pivotal event leading to significant changes in adoption of Afrezza by healthcare professionals, academics, patients and families of patients. If if elected by shareholders to a director seat, I would have very focused questions about progress to date and assertive forward planning. |
|
